原標(biāo)題：調(diào)節(jié)人IgE與樺樹花粉主要過敏原Bet v 1結(jié)合的單克隆抗體的免疫學(xué)特征
　?、俦尘埃航?5%的樹花粉過敏患者和近70%的水果和蔬菜過敏患者的主要過敏原是Bet v1和同源蛋白。到目前為止，還沒有確定Bet v1的連續(xù)IgE表位，也有證據(jù)表明Bet v1 IgE表位屬于構(gòu)象(不連續(xù))型。②目的：以85只小鼠單克隆抗Bet v1抗體為研究對(duì)象，研究人IgE抗體與Bet v1的相互作用。③方法:采用合成重疊多肽圖譜和交叉競爭實(shí)驗(yàn)對(duì)單克隆抗體表位進(jìn)行鑒定。采用Western blot方法研究了Bet v1特異性單克隆抗體與樹花粉、植物性食物過敏原的交叉反應(yīng)。采用固化重組Bet v1（純化）競爭實(shí)驗(yàn)和嗜堿性組胺釋放實(shí)驗(yàn)研究了Bet v1特異性單克隆抗體對(duì)IgE-Bet v1相互作用的影響。④結(jié)果:能使結(jié)合到Bet v1的IgE抗體最多可增加5倍，而其他抗體可抑制結(jié)合到Bet v1的IgE抗體最多可達(dá)99%，并與Bet v1誘導(dǎo)的患者嗜堿性粒細(xì)胞組胺釋放相競爭。⑤結(jié)論: Bet v1特異性抗體的活性被解釋為Bet v1狀態(tài)/IgE表位的穩(wěn)定性，這些表位要么更易被某些IgE抗體獲得，要么被認(rèn)為具有更高的親和力。那些與Bet v1 -IgE相互作用競爭的單克隆抗體，如果被人化處理或作為重組抗體片段生產(chǎn)，可能被認(rèn)為是局部過敏治療的潛在工具。


　　延伸閱讀
JACI:
Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1
https://doi.org/10.1016/S0091-6749(97)70056-3
Abstract:
Background
Background: Bet v 1 and homologous proteins represent major allergens for almost 95% of patients allergic to tree pollen and approximately 70% of those allergic to fruits and vegetables. As yet, no continuous (sequential) IgE epitopes have been determined for Bet v 1, and evidence has accumulated that Bet v 1 IgE epitopes belong to the conformational (discontinuous) type. Objective: A panel of 85 mouse monoclonal anti-Bet v 1 antibodies was raised as a tool with which to study the interaction of human IgE antibodies with Bet v 1. Methods: The epitopes of selected monoclonal antibodies (mAbs) were characterized by mapping with synthetic overlapping peptides and by cross-competition experiments. Cross-reactivity of Bet v 1–specific mAbs with tree and plant food allergens was investigated by Western blotting. The influence of Bet v 1–specific mAbs on the IgE–Bet v 1 interaction was studied by competition assays with immobilized purified recombinant Bet v 1 and by basophil histamine release experiments. Results: Antibodies that increased the IgE binding to Bet v 1 up to fivefold could be defined, whereas others inhibited IgE binding to Bet v 1 up to 99% and competed with the Bet v 1–induced histamine release from patients' basophils. Conclusion: The activity of the enhancing antibodies is interpreted as a stabilization of Bet v 1 states/IgE epitopes, which are either more accessible for certain IgE antibodies or are recognized with higher affinity. Those mAbs that competed with the Bet v 1–IgE interaction, if humanized or produced as recombinant antibody fragments, might be considered as potential tools for local allergy therapy. (J Allergy Clin Immunol 1997;99:374-84.)
All Author:
Serge Lebecque, MDa, Christiane Dolecek, MDb, Sylvia Lafferb, Vincenzo Visco, PhDa, Stéphanie Denépouxa, Jean-Jacques Pina, Christiane Gureta, George Boltz-Nitulescu, PhDb, Anne Weyer, PhDc, Rudolf Valenta, MDb
　　創(chuàng)建過敏性疾病的科研、科普知識(shí)交流平臺(tái)，為過敏患者提供專業(yè)診斷、治療、預(yù)防的共享平臺(tái)。